C4 Therapeutics (CCCC) Operating Leases (2019 - 2026)

C4 Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $51.9 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 11.16% year-over-year to $51.9 million in Q1 2026; TTM through Mar 2026 was $51.9 million, a 11.16% decrease from a year earlier, with the FY2025 full-year figure at $53.6 million, down 10.61% from the prior year.
• Operating Leases eased to $51.9 million in Q1 2026 per CCCC's latest filing, from $53.6 million in the prior quarter.
• Across five years, Operating Leases topped out at $75.2 million in Q2 2022 and bottomed at $51.9 million in Q1 2026.
• The 5-year median for Operating Leases is $64.4 million (2024), against an average of $64.1 million.
• Across the five-year window, Operating Leases surged 569.59% in 2022 and decreased 11.16% in 2026, its largest moves.
• Year by year, Operating Leases stood at $71.0 million in 2022, then fell by 7.35% to $65.8 million in 2023, then fell by 8.78% to $60.0 million in 2024, then slipped by 10.61% to $53.6 million in 2025, then fell by 3.15% to $51.9 million in 2026.
• Per Business Quant, the three latest CCCC Operating Leases figures stand at $51.9 million (Q1 2026), $53.6 million (Q4 2025), and $55.2 million (Q3 2025).